423 related articles for article (PubMed ID: 34729904)
1. Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery.
Martínez-Montoro JI; Kuchay MS; Balaguer-Román A; Martínez-Sánchez MA; Frutos MD; Fernández-García JC; Ramos-Molina B
Obes Rev; 2022 Feb; 23(2):e13367. PubMed ID: 34729904
[TBL] [Abstract][Full Text] [Related]
2. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
3. Is bariatric surgery resolving NAFLD via microbiota-mediated bile acid ratio reversal? A comprehensive review.
Talavera-Urquijo E; Beisani M; Balibrea JM; Alverdy JC
Surg Obes Relat Dis; 2020 Sep; 16(9):1361-1369. PubMed ID: 32336663
[TBL] [Abstract][Full Text] [Related]
4. Mining Gut Microbiota From Bariatric Surgery for MAFLD.
Wu WK; Chen YH; Lee PC; Yang PJ; Chang CC; Liu KL; Hsu CC; Huang CC; Chuang HL; Sheen LY; Liu CJ; Wu MS
Front Endocrinol (Lausanne); 2021; 12():612946. PubMed ID: 33897617
[TBL] [Abstract][Full Text] [Related]
5. Gut Microbiota and Plasma Bile Acids Associated with Non-Alcoholic Fatty Liver Disease Resolution in Bariatric Surgery Patients.
Pérez-Rubio Á; Soluyanova P; Moro E; Quintás G; Rienda I; Periañez MD; Painel A; Vizuete J; Pérez-Rojas J; Castell JV; Trullenque-Juan R; Pareja E; Jover R
Nutrients; 2023 Jul; 15(14):. PubMed ID: 37513605
[TBL] [Abstract][Full Text] [Related]
6. The role of the microbiome in NAFLD and NASH.
Kolodziejczyk AA; Zheng D; Shibolet O; Elinav E
EMBO Mol Med; 2019 Feb; 11(2):. PubMed ID: 30591521
[TBL] [Abstract][Full Text] [Related]
7. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
Boursier J; Mueller O; Barret M; Machado M; Fizanne L; Araujo-Perez F; Guy CD; Seed PC; Rawls JF; David LA; Hunault G; Oberti F; Calès P; Diehl AM
Hepatology; 2016 Mar; 63(3):764-75. PubMed ID: 26600078
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: Correlation and causality.
Xia Y; Ren M; Yang J; Cai C; Cheng W; Zhou X; Lu D; Ji F
Front Microbiol; 2022; 13():1003755. PubMed ID: 36204626
[TBL] [Abstract][Full Text] [Related]
9. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
Jayakumar S; Loomba R
Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice.
Zhuge A; Li S; Lou P; Wu W; Wang K; Yuan Y; Xia J; Li B; Li L
Microbiol Spectr; 2022 Jun; 10(3):e0004722. PubMed ID: 35647690
[TBL] [Abstract][Full Text] [Related]
11. Integrative metabolomics highlights gut microbiota metabolites as novel NAFLD-related candidate biomarkers in children.
Luo J; Luo M; Kaminga AC; Wei J; Dai W; Peng Y; Zhao K; Duan Y; Xiao X; Ouyang S; Yao Z; Liu Y; Pan X
Microbiol Spectr; 2024 Apr; 12(4):e0523022. PubMed ID: 38445874
[TBL] [Abstract][Full Text] [Related]
12. Role of intestinal flora in the development of nonalcoholic fatty liver disease in children.
Zhang J; Shi M; Zhao C; Liang G; Li C; Ge X; Pei C; Kong Y; Li D; Yang W; Cao B; Fu L; Yan Y; Wu J; Zhou J; Fang Y; Meng X; Li Y; Wang L
Microbiol Spectr; 2024 Feb; 12(2):e0100623. PubMed ID: 38189294
[TBL] [Abstract][Full Text] [Related]
13. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
[TBL] [Abstract][Full Text] [Related]
14. The role of bariatric surgery in the management of nonalcoholic steatohepatitis.
Seymour KA; Abdelmalek MF
Curr Opin Gastroenterol; 2021 May; 37(3):208-215. PubMed ID: 33769376
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm.
Ghoshal UC; Goel A; Quigley EMM
Indian J Gastroenterol; 2020 Feb; 39(1):9-21. PubMed ID: 32291578
[TBL] [Abstract][Full Text] [Related]
16. Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut-Liver Axis.
Cerreto M; Santopaolo F; Gasbarrini A; Pompili M; Ponziani FR
Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444807
[TBL] [Abstract][Full Text] [Related]
17. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
Chen YH; Wu WK; Wu MS
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
[TBL] [Abstract][Full Text] [Related]
18. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.
Tsai MC; Liu YY; Lin CC; Wang CC; Wu YJ; Yong CC; Chen KD; Chuah SK; Yao CC; Huang PY; Chen CH; Hu TH; Chen CL
Nutrients; 2020 Mar; 12(3):. PubMed ID: 32204538
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy.
Fianchi F; Liguori A; Gasbarrini A; Grieco A; Miele L
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204274
[TBL] [Abstract][Full Text] [Related]
20. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
